Concepedia

Peter A. Riedell

PA

Statistics

Publications

76

Citations

5.4K

H-Index

31

Active since

2015

Affiliations

University of Chicago(Current)

The University of Texas MD Anderson Cancer Center

Moffitt Cancer Center

Memorial Sloan Kettering Cancer Center

City Of Hope National Medical Center

Peter A. Riedell is an author at University of Chicago specializing in oncology, medicine, and immunotherapy.

Publications per year

2015–2025

76

Publications

76

Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma

Frederick L. Locke, David B. Miklos, Caron A. Jacobson et al. · New England Journal of Medicine · 2021 · 1.5K citations · Full text

Medicine, Hematology, Oncology +8

Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial

Nathan Fowler, Michael Dickinson, Martin Dreyling et al. · Nature Medicine · 2021 · 527 citations · Full text

Medicine, Hematology, Oncology +12

Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma

Jason R. Westin, Olalekan O. Oluwole, Marie José Kersten et al. · New England Journal of Medicine · 2023 · 410 citations · Full text

Medicine, Immunology, Oncology +17

Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial

Sattva S. Neelapu, Michael Dickinson, Javier Muñoz et al. · Nature Medicine · 2022 · 283 citations · Full text

Medicine, Hematology, Oncology +17

Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study

Alison R. Sehgal, Daanish Hoda, Peter A. Riedell et al. · The Lancet Oncology · 2022 · 234 citations

Medicine, Hematology, Oncology +14

1–5 of 76